Drug, across the briefings
Osimertinib across 12 cancers
Osimertinib appears in 12 of the briefings; its FDA label names 1 of those diseases.
| Disease | FDA label | Open Targets stage, on which gene | Trials | Active |
|---|---|---|---|---|
| Lung cancer | label names disease | approved on EGFR | 162 | 95 |
| Anal cancer | approved on EGFR | — | — | |
| Cervical cancer | approved on EGFR | 3 | 2 | |
| Colorectal cancer | approved on EGFR | 5 | 3 | |
| Cutaneous squamous cell carcinoma | approved on EGFR | — | — | |
| Esophageal cancer | approved on EGFR | 3 | 2 | |
| Gallbladder cancer | approved on EGFR | — | — | |
| Glioblastoma | approved on EGFR | 2 | 1 | |
| Head and neck cancer | approved on EGFR | 4 | 4 | |
| Nasopharyngeal carcinoma | approved on EGFR | — | — | |
| Pancreatic cancer | approved on EGFR | 3 | 1 | |
| Vulvar cancer | approved on EGFR | — | — |
The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.